This inventor holds 3 USPTO granted patents. Top assignee: Japan Energy Corporation. Active years: 1999-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999-2001
Title: Ryohei Kato: Innovator in Dipeptide Compounds
Introduction
Ryohei Kato is a notable inventor based in Toda, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel dipeptide compounds. With a total of 3 patents to his name, Kato's work focuses on innovative methodologies that enhance the efficacy of treatments for diseases such as HIV.
Latest Patents
Kato's latest patents include methods for preparing novel dipeptide compounds and their pharmaceutically acceptable salts. These compounds exhibit excellent HIV protease inhibitory activity and demonstrate remarkable bioavailability from digestive tracts. One of his notable inventions provides a synthetic methodology to produce these compounds, which can be utilized as effective anti-AIDS agents. The general formula for a non-limiting example of a dipeptide compound from his invention includes various hydrocarbon and heterocyclic groups, showcasing the complexity and potential of his work.
Career Highlights
Kato is currently associated with Japan Energy Corporation, where he continues to innovate in the field of pharmaceutical compounds. His research has the potential to significantly impact the treatment of HIV and related conditions, making him a key figure in pharmaceutical research.
Collaborations
Kato has collaborated with notable coworkers such as Tsutomu Mimoto and Tominaga Fukazawa. Their combined expertise contributes to the advancement of research in dipeptide compounds and their applications.
Conclusion
Ryohei Kato's contributions to the field of pharmaceutical chemistry through his innovative patents on dipeptide compounds highlight his role as a significant inventor. His work not only advances scientific knowledge but also holds promise for improving treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile